The association of sickle cell disorder with adverse outcomes in COVID‐19 patients: A meta‐analysis

Abstract

AbstractThe aim is to elucidate the relationship between sickle cell disorder and severe COVID‐19. We systematically searched the required articles in three electronic databases, extracting and pooling effect sizes (ES) and 95% confidence interval (CI) from each eligible study to evaluate the effect of combined sickle cell disorder on adverse consequences in patients with COVID‐19. This meta‐analysis included 21 studies. Sickle cell disease (SCD) was a risk factor for mortality (pooled ES = 1.70, 95% CI: 1.00–2.92, p = 0.001), hospitalization (pooled ES = 6.21, 95% CI: 3.60–10.70, p = 0.000) and intensive care unit (ICU) admission (pooled ES = 2.29, 95% CI: 1.61–3.24, p = 0.099) in COVID‐19 patients. Patients with SCD had an increased risk of respiratory failure/mechanical ventilation, but a statistical association was not found (pooled ES = 1.21, 95%CI: 0.74‐1.98, p = 0.036). There was significant heterogeneity between SCD and death, hospitalization, and respiratory failure/mechanical ventilation. The results of meta‐regression of SCD and hospitalization suggested that the tested variables including Area (p = 0.642), study design (p = 0.739), sample size (p = 0.397), proportion of males (p = 0.708), effect type (p = 0.723), whether confounding factors are adjusted (p = 0.606) might not be the source of heterogeneity. In addition, sickle cell trait (SCT) was significantly associated with the mortality (pooled ES = 1.54, 95% CI: 1.28–1.85, p = 0.771) and hospitalization (pooled ES = 1.20, 95% CI: 1.07–1.35，p = 0.519) in patients with COVID‐19. But any increased risk of ICU admission/severe (pooled ES = 1.24, 95% CI: 0.95–1.62, p = 0.520) and mechanical ventilation (OR = 1.00, 95%CI:0.59‐1.69) in COVID‐19 patients with SCT was not observed. Sensitivity analysis demonstrated that the results were robust. The results of the funnel plot and Egger's test did not support the existence of publication bias. Current meta‐analysis indicated that sickle cell disorder has a meaningful impact on COVID‐19 progression to severe cases and associated deaths. However, further investigations and research to validate the current findings is indispensable.